SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Collage art of a hand touching a cat. Modern and creative design with surreal style. Perfect for use in posters, editorial design, social media, digital art, and contemporary art projects
Allergies
Regeneron’s Antibodies Block Cat and Birch Allergies With ‘Robust Activity’
Regeneron’s antibody duos significantly lowered eye itching and redness, as well as pin prick reactivity, in people with cat and birch allergies. Still, BMO Capital Markets expressed uncertainty about the assets’ “commercial potential in a highly generic market.”
September 9, 2025
 · 
2 min read
 · 
Tristan Manalac
FDA recently approved BESREMi for the treatment of
Manufacturing
As Ori Wins Designation, FDA’s Advanced Manufacturing Program Nears Proof Point
Ori Biotech’s CEO said the prioritization of review by FDA, coupled to the impact of the technology, could shave up to three years off development timelines.
September 9, 2025
 · 
5 min read
 · 
Nick Paul Taylor
Biogen’s headquarters in Massachusetts
Immunology and inflammation
Lupus Reveal Gives Investors a Peek at Biogen’s ‘Underappreciated’ Pipeline
With two late-stage programs set to read out in the next 48 months, Biogen is translating its wealth of experience in multiple sclerosis to lupus—developing a pipeline BMO Capital Markets analysts called “thoughtful.”
September 9, 2025
 · 
4 min read
 · 
Heather McKenzie
Modern data center with AI server racks connected by glowing blue lines, representing artificial intelligence, advanced computing, and data processing.
Drug Development
If Data Is the New Oil, AI Is the Refinery
The 2025 Bioprocessing Summit revealed knowledge gaps and changing mindsets. As some companies look towards the future, others struggle with the present and past.
September 8, 2025
 · 
5 min read
 · 
Lori Ellis
Contemporary art collage of woman sitting in the lotus position, cloud, pillows against the background of the night sky. Concept of healthy lifestyle and sport. Good and relaxing sleep. Copy space.
Neuroscience
Alkermes One Ups Takeda in Narcolepsy, Clearing Cognitive Impairments in Mid-Stage Trial
Presenting at the World Sleep Congress 2025, the Dublin-based company’s Phase II study bested Takeda drug in both efficacy and safety.
September 8, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Modern collage with halftone hand holding pencil and drawing check mark. Confirmation. Concepts of agreement and choice
FDA
FDA Demurs on GLP-1 Compounding Fight, Debuts Consumer ‘Green List’ Instead
While a win for consumers, the regulatory action did nothing to stem the manufacture of compounded versions of the popular obesity drugs that are made by Novo Nordisk and Eli Lilly. In fact, the FDA seems to be signaling that “some level of compounded product is acceptable,” according to BMO Capital Markets.
September 8, 2025
 · 
2 min read
 · 
Annalee Armstrong
Blue growth graph business chart data diagram on success financial presentation background with abstract up arrow bar symbol or finance marketing price statistic and economy market profit investment.
Neuroscience
Rapport Jumps 180% on ‘Best Case’ Mid-Stage Data for Epilepsy Pill
Shares of Rapport Therapeutics popped Monday morning after Phase IIa data for RAP-219 exceeded analyst and Wall Street expectations, reducing seizures by almost 78% in patients with drug-resistant focal onset seizures.
September 8, 2025
 · 
2 min read
 · 
Heather McKenzie
Employees wonder how to evaluate job security
Lung cancer
Summit’s Keytruda Challenger Hits Cross-Country Consistency Problems, Raising US Approval Questions
Ivonescimab elicited better overall survival in Asian patients with non-small cell lung cancer than in those from North America and European countries, in Western countries narrowly missing the statistical significance threshold the FDA is seeking.
September 8, 2025
 · 
2 min read
 · 
Tristan Manalac
Sponsored
WHITE PAPER: Validated devices for easy self-collection and stabilization of vaginal microbiome samples
The vaginal microbiome plays a critical role in women’s health, from infection resistance to fertility, yet it continues to remain underexplored. With DNA Genotek™’s OMNIgene™•VAGINAL collection kit, researchers and innovators are empowered to collect stablized samples with precision to support women’s healthcare research and development of healthcare for women.
September 8, 2025
 · 
1 min read
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS